BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
← catalyst calendarNCT02051062 · readout in 712 d
Sponsored by Emergent BioSolutions (industry) · EBS — their whole pipeline →.
Phase
Phase 4
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Basic science
Enrollment
10estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2014 | actual | When the study began enrolling |
| Primary completion | 2028-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2014-01-31 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Botulism
Intervention
- Biological: Blood sample collection
Primary outcome
what the primary-completion date above is the date OFMargin of PK Equivalence for 90% Survival
measured ideally up to 32 hours post-BAT product administration
Publications
- PMID 31209461 — cited as background
- PMID 35050996 — cited as background
- PMID 35467014 — cited as background
- PMID 33956777 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EBS's whole pipeline · Catalyst calendar · Every registered study · What changed